The funding will be used to advance the firm’s patented epigenetic editing in non-human primates, expand expertise and capabilities, and fund early-stage clinical research
Biotechnology company Epigenic Therapeutics has secured $20m in Series Angel and Pre-A funding to advance the firm’s patented epigenetic editing in non-human primates.
According to the firm, the funding will also be used to expand expertise and capabilities, and fund early-stage clinical research.
Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital along with Angel investor FountainBridge Capital have participated in the Series Pre-A funding round.
Epigenetic modification regulates genes naturally and heritably without changing the underlying DNA sequence in the human body, said Epigenic Therapeutics.
Using the company’s patented technology, scientists are able to use the endogenous epigenetic gene regulatory system to deliver medication to target cells and tissues and achieve a powerful and long-lasting therapeutic effect.
To oversee research and development, Epigenic Therapeutics has gathered a team of very qualified scientists and business experts.
The patented technological platform of the firm uses its own artificial intelligence (AI) algorithms to investigate and find an optimum CRISPR-Cas component.
It helps to control target gene(s) or regulate the expression of one or more genes simultaneously without altering the DNA sequence.
The firm’s technology, when compared to competing technologies, is able to avoid possible risks associated with DNA cleavage, such as off-target effects, short half-lives, and difficult patient compliance concerns.
Epigenic Therapeutics co-founder and CEO Bob Zhang said: “Epigenetic editing is an emerging and highly differentiated gene editing technology.
“Along with our scientific co-founders and advisers, we are able to expand our understanding of precise regulation of epigenetic genome, and unlock its potential as medicine for many diseases.
“With the funding, we will continue expanding our team and capabilities, validate the technology platform in animal model, and accelerate our leading product from discovery to clinical development.”